Know Cancer

or
forgot password

Letrozole Versus Laparoscopic Ovarian Diathermy for Ovulation Induction in Clomiphene-resistant Women With Polycystic Ovary Syndrome


N/A
20 Years
36 Years
Not Enrolling
Female
Polycystic Ovary Syndrome

Thank you

Trial Information

Letrozole Versus Laparoscopic Ovarian Diathermy for Ovulation Induction in Clomiphene-resistant Women With Polycystic Ovary Syndrome


In the letrozole group, withdrawal bleeding was achieved using 10 mg of dydrogesterone
tablets for 10 days before stimulation, then 2.5 mg of letrozole oral tablets (Femara;
Novartis Pharma Services, Switzerland) daily from day 3 of the menses for 5 days up to six
cycles. All patients in the control group underwent laparoscopic ovarian diathermy, then
followed up for 6 months.


Inclusion Criteria:



- CC resistant PCOS

Exclusion Criteria:

- Congenital adrenal hyperplasia

- Cushing syndrome

- Androgen secreting tumors

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

occurrence of ovulation and midcycle endometrial thickness (mm).

Safety Issue:

No

Principal Investigator

Hatem Abu Hashim, MD. MRCOG

Investigator Role:

Principal Investigator

Investigator Affiliation:

Mansoura University Hospitals

Authority:

Egypt: Institutional Review Board

Study ID:

MU- 094

NCT ID:

NCT00956267

Start Date:

August 2006

Completion Date:

March 2009

Related Keywords:

  • Polycystic Ovary Syndrome
  • Polycystic ovary syndrome
  • clomiphene resistance
  • letrozole
  • Laparoscopic ovarian diathermy
  • Polycystic Ovary Syndrome

Name

Location